反应堆产医用同位素及药物的创新发展研究  

Innovative Development of Reactor-Produced Radionuclides and Radiopharmaceuticals

作　　者：彭述明[1] 杨宇川[1] 杨夏[1] 贾尧丹 黄曾[1] 郑刚阳 赵宪庚[4] Peng Shuming;Yang Yuchuan;Yang Xia;Jia Yaodan;Huang Zeng;Zheng Gangyang;Zhao Xiangeng(Institute of Nuclear Physics and Chemistry,China Academy of Engineering Physics,Mianyang 621900,Sichuan,China;School of Medicine,Tsinghua University,Beijing 100084,China;Chinese Academy of Engineering Innovation Strategy,Beijing 100088,China;Chinese Academy of Engineering Physics,Beijing 100088,China)

机构地区：[1]中国工程物理研究院核物理与化学研究所,四川绵阳621900 [2]清华大学医学院,北京100084 [3]中国工程科技创新战略研究院,北京100088 [4]中国工程物理研究院,北京100088

出　　处：《中国工程科学》2024年第2期224-233,共10页Strategic Study of CAE

基　　金：中国工程院咨询项目“我国核医疗健康产业链自立自强研究”(2022-HYZD-06)。

摘　　要：医用同位素及药物是核医疗健康产业的重要组成部分和主要物质基础,系统梳理反应堆产同位素及药物发展现状对于加快我国同位素及药物发展、推动自立自强全链条体系建设具有现实意义。本文采用文献调研、问卷调查、实地调研、行业研讨等方法,分析了国内外反应堆产医用同位素及药物的供需情况、发展现状与趋势。研究发现,目前我国仅实现了131I、177Lu、89Sr等反应堆产医用同位素的自主供给,但供给量尚未完全满足国内需求,多数临床常用的同位素依然依赖进口;反应堆产同位素相关的放射性药物存在药品种类少、研发创新不足、生产规模小等瓶颈,难以满足临床实际需要。研究建议,研判供需现状与趋势,实现反应堆产医用同位素供给与品种的多元化;以临床需求为牵引,带动反应堆产医用同位素的规模化制备,支持放射性药物的研发与应用创新,加快建设反应堆产医用同位素及其放射性药物的自立自强发展体系;丰富发展模式并形成创新观念,为我国核医疗持续发展提供坚实保障。Radionuclides and radiopharmaceuticals produced by reactors are important components and main material foundations of the nuclear healthcare industry.Therefore,summarizing the current status of reactor-produced radionuclides and radiopharmaceuticals is practically significant for accelerating the development of these products in China and promoting the construction of a self-reliant full-chain system.Through literature review,questionnaire survey,field research,and industry discussions,this study analyzes the supply and demand situation,current status,and trends of reactor-produced radionuclides and radiopharmaceuticals in China and abroad.Currently,China has achieved independent supply of a small number of reactor-produced radionuclides such as 131I,177Lu,and 89Sr;however,the production capacity of these radionuclides cannot meet domestic demand,and most commonly used radionuclides in clinical practice still rely on imports.Meanwhile,the current reactor-produced radiopharmaceuticals face bottlenecks such as a limited variety of drugs,insufficient research and development innovation,and limited production capacity,making it difficult to meet actual clinical needs.Therefore,the supply and diversification of reactor-produced radionuclides should be ensured considering the current status and trends of their supply and demand.It is necessary to promote the large-scale preparation of reactor-produced radionuclides based on clinical needs,support the development and application of more innovative radiopharmaceuticals,and further accelerate the formation of a self-reliant development system for the reactor-produced radionuclides and radiopharmaceuticals in China.Additionally,it is urgent to enrich development models and form innovative concepts,providing reliable support for the sustainable development of nuclear medicine in China.

关 键 词：反应堆 医用放射性同位素 放射性药物 供需现状 自主化 

分 类 号：TL99[核科学技术—核技术及应用]